HANSOH PHARMA (03692) has announced that its independently developed Class 1 new drug, HS-10582 tablets, has received a clinical trial approval notice from China's National Medical Products Administration (NMPA).
The company plans to conduct clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.